Stockscreener 앱 받기
0.5024
6.39%
-0.0343
시간 외 거래:
.52
0.0176
+3.50%
Conduit Pharmaceuticals Inc 주식(CDT)의 최신 뉴스
Conduit Pharmaceuticals Inc (CDT)’s highs and lows: A closer look at its stock price fluctuations - uspostnews.com
Short Interest in Conduit Pharmaceuticals Inc. (NASDAQ:CDT) Increases By 98.5% - Defense World
Keeping an Eye on Conduit Pharmaceuticals Inc (CDT) After Insider Trading Activity - knoxdaily.com
Conduit Pharmaceuticals Inc (CDT)’s Day in Review: Closing at 0.56, Up by 4.07 - DWinneX
Investor’s Delight: Conduit Pharmaceuticals Inc (CDT) Closes Weak at 0.65, Down -5.79 - DWinneX
Conduit Pharmaceuticals (NASDAQ:CDT) Stock Price Down 2.9% – Time to Sell? - Defense World
What Do Wall Street Analysts Think About Conduit Pharmaceuticals Inc (NASDAQ: CDT) Stock? - Stocksregister
Conduit Pharmaceuticals files to sell 2.1M shares of common stock for holders - MSN
Conduit Pharmaceuticals Inc’s latest rating changes from various analysts - knoxdaily.com
Are Conduit Pharmaceuticals Inc (CDT) shares a good deal now? - uspostnews.com
Market Resilience: Conduit Pharmaceuticals Inc (CDT) Finishes Weak at 0.62, Down -20.51 - DWinneX
CDT’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - investchronicle.com
CDTConduit Pharms Latest Stock News & Market Updates - Stock Titan
Conduit Pharmaceuticals Announces Leadership Changes - marketscreener.com
Conduit Pharmaceuticals Announces Novel Cocrystal Patent Filing For Vtama® - MarketScreener
Strategic Patent Filing Could Transform VTAMA's $233B Market Potential - Stock Titan
Conduit Pharmaceuticals Announces up to $1,000,000 Share Repurchase Program - The Manila Times
Conduit Pharmaceuticals expands partnership with Sarborg - MSN
Conduit Pharmaceuticals Expands Partnership with Sarborg Limited to Leverage Machine Learning Data Analysis for Pipeline Optimization - The Manila Times
Machine Learning Deal: How Conduit Pharma Plans to Revolutionize Drug Development - Stock Titan
Analyzing Conduit Pharmaceuticals (CDT) and Its Competitors - Defense World
Conduit Pharmaceuticals meets Nasdaq listing standards By Investing.com - Investing.com Australia
Conduit Pharmaceuticals meets Nasdaq listing standards - Investing.com
Conduit Pharmaceuticals Receives U.S. Patent Approval For Its Lead Asset Targeting Autoimmune Diseases - The Manila Times
Major Patent Win: Conduit's Autoimmune Drug Gets 20-Year Market Protection - Stock Titan
Conduit Pharmaceuticals Inc. (CDT) reports earnings - Quartz
CONDUIT PHARMACEUTICALS INC. SEC 10-K Report - TradingView
CONDUIT PHARMACEUTICALS INC- The GF Score's 5 Key Aspects of Analysis - GuruFocus.com
Conduit Pharma Highlights Progress In Lupus Studies, Phase II Trial For AZD1656 - Nasdaq
Conduit Pharmaceuticals progresses in autoimmune drug studies By Investing.com - Investing.com Australia
Conduit Pharmaceuticals progresses in autoimmune drug studies - Investing.com
Conduit Pharmaceuticals Provides Research and Development Update on Progress for Pipeline Assets AZD1656, AZD5658, and AZD5904 - The Manila Times
Conduit Pharmaceuticals Reports Significant R&D Advancements in Lupus Studies and Pipeline Development - Nasdaq
Conduit's Triple-Drug Pipeline Shows Promise for Lupus TreatmentMajor R&D Breakthrough - StockTitan
A closer look at Conduit Pharmaceuticals Inc (CDT)’s stock price trends - uspostnews.com
Conduit Pharmaceuticals Inc. (NASDAQ:CDT) Short Interest Update - The AM Reporter
Is Conduit Pharmaceuticals Inc. (CDT) the Best Micro Cap Stock to Buy Now? - Insider Monkey
Conduit Pharmaceuticals Gets Nasdaq Extension, Plans Capital Market Transfer - MarketScreener
Conduit Pharmaceuticals Provides Update on Nasdaq Stock Market Hearing Panel - The Manila Times
Conduit Pharmaceuticals secures Nasdaq extension - Investing.com
Conduit Pharmaceuticals Secures Extension for Nasdaq Compliance Following Bid Price Regaining - Nasdaq
Can Conduit Pharmaceuticals Keep Its Nasdaq Listing? Critical Deadlines Ahead - StockTitan
Conduit Pharmaceuticals secures Nasdaq extension By Investing.com - Investing.com Australia
Conduit Pharmaceuticals Inc (NASDAQ: CDT) Is Down -83.09% So Far This Year: What Will Happen Next? - Stocks Register
Taking a look at what insiders are doing to gauge the Conduit Pharmaceuticals Inc (CDT)’s direction - Knox Daily
Conduit Pharmaceuticals Inc (CDT) requires closer examination - uspostnews.com
Conduit Pharmaceuticals Advances Phase II AI Collaboration With Sarborg To Enhance Drug Development - Nasdaq
Conduit Progresses Phase II of its AI Initiative with Sarborg - The Manila Times
How Conduit's New AI System Could Revolutionize Drug Development Decision-Making - StockTitan
0.39%
3.66%
자본화:
|
볼륨(24시간):